Immix Biopharma Investor Presentation Deck

IMX-110 Preclinical Data Provides Translational Rationale & PD-1 Combination Rationale 50% 0% (50%) (100%) Percent Survival After One Cycle of Treatment At Day 22 75% IMX-110 Demonstrated Improved Survival iMX-110 IMX-110 Demonstrated Response Rate Better than Standard of Care Best % Change from Baseline in Size of Tumor +23% Trabectedin (sold as YONDELIS by Janssen, a Johnson & Johnson Company) 0% (41%) Standard of Care IMX-110 Treatment Treatment Group: Group: Responder Entire Group Mean (32%) • In a connective tissue cancer Soft Tissue Sarcoma (STS) mice study, IMX-110 was compared against approved drugs ¡MX-110 Treatment Group: Entire Group Mean • One cycle of IMX-110 produced 75% survival vs. 0% survival for Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company, a U.S. FDA approved drug) May 20, 2022 Press Release • IMX-110 produced a 50% response rate after 1 cycle of treatment as a monotherapy in first-line- therapy-resistant cancer soft tissue sarcoma (STS) mice study • IMX-110 response rate surpassed standard of care doxorubicin's response rate of 0% after 1 cycle of treatment in the same study January 12, 2022 Press Release ● Median Survival In Genetic (KPC) Pancreatic Cancer Mouse Model IMX-110 +anti-PD-1 Potential Survival Benefit Better than Comparable Median Survival 63 days IMX-110 + anti-PD-1 IMMIX BIOPHARMA A50%! 05070 42 days 4-drug combination 2 chemotherapies (gemcitabine, nab-paclitaxel) and 2 immunotherapies (anti-PD-1, anti-CD40) Source: Inmix Biopharma, Inc. Adapted from Winograd, et al, 2015 January 25, 2022 10:15 ET | Source: Immix Biopharma, Inc. ●●● ● BIOPHARMA • IMX-110 + anti-PD-1 produced 63-day median survival in a genetic (KPC) pancreatic cancer mouse model in which mice develop their own pancreatic cancer and have an intact immune system ● Historically, 42-days is the median survival produced by a 4-drug combination of 2 chemotherapies and 2 immunotherapies in the same genetic pancreatic cancer mouse model according to Winograd et al., 2015 • 2022 plan to commence combination IMX- 110 + BeiGene anti-PD-1 tislelizumab Phase 1b/2a clinical trial in advanced solid tumors January 25, 2022 Press Release IMX-110 + anti-PD-1 Combination Produced Extended Median Survival in Genetic Pancreatic Cancer Mouse Model, Bolstering Planned 2022 IMX-110 Combination Clinical Trial Rationale 44 5

View entire presentation